Investing.com - Grifols ADR (NASDAQ: GRFS) reported second quarter EPS of $0.19, $0.01 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $1.84B versus...
Investing.com - Grifols ADR (NASDAQ: GRFS) reported first quarter EPS of $0.04, $0.12 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $1.7B versus the...
BARCELONA (Reuters) -Spanish drugmaker Grifols on Tuesday lifted its 2023 margin outlook after reporting sturdy growth in first-quarter core earnings and revenue as cost-cutting...
By Joan Faus BARCELONA (Reuters) -Grifols said on Monday its executive chairman Thomas Glanzmann will become its new chief executive with immediate effect, ending the founding...
Investing.com - Grifols ADR (NASDAQ: GRFS) reported fourth quarter EPS of $0.06, $0.17 worse than the analyst estimate of $0.24. Revenue for the quarter came in at $1.82B versus...
By Joan Faus and Matteo Allievi BARCELONA (Reuters) -Spanish pharmaceutical company Grifols' shares fell around 10% in afternoon trading after its 2023 outlook disappointed...
MADRID (Reuters) - Steven F. Mayer has resigned as executive chairman of the board of Spanish pharmaceutical company Grifols, the company said on Tuesday, citing health and other...
Grifols (GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines, today announced that its recently concluded phase 4 trial (NCT04566692)...